Ultralow Dose PET Imaging of 18F-FDG Uptake

Part of paid clinical trials in Englewood, New Jersey.

Sponsor
Akiva Mintz
Study ID
NCT06956391
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Cancer
  • Healthy Volunteer

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Accepted

Interventions

  • 18F-FDG — DRUG
    Participants will be injected with 18F-FDG and imaged for up to 3 hours on a PET scanner

Study Details

The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for cancer detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-FDG and be imaged on a new type of high-sensitivity PET scanner for up to 3 hours.

Key Dates

Start date
May 12, 2025
Status verified
Apr 2025
Primary completion
Jun 30, 2030
Completion
Jun 30, 2030

Study Design

Enrollment
200 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Ultralow Dose 18F-FDG Imaging Group

Primary Outcome Measure

Signal-to-Noise Ratio (SNR) [ Time Frame: Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Nuclear Imaging InstituteEnglewoodNew Jersey07631
Barbara Blanchfield
[email protected]
973-255-4955

Find similar trials in Englewood, NJ

By research site
Nuclear Imaging Institute· Englewood, NJ

Related Studies